HIGHLIGHTS
- who: Hao Sun from the Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China have published the research: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives, in the Journal: (JOURNAL)
- what: Tumor Treg and MDSC are the main reasons for the failure of tumor immunotherapy. This study is to evaluate the safety, tolerability, pharmacokinetics(PK)/pharmacodynamics(PD) and preliminary efficacy of DN1508052 as monotherapy and in combination with anti-PD-1 mAbs (Toripalimab) in patients with advanced solid tumors after standard treatment or without standard treatment.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.